Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 16/20 | 0.71 |
| ▸ | HTR1B | P28222 | 16/20 | 0.71 |
| ▸ | HTR1A | P08908 | 6/20 | 0.55 |
| ▸ | GHSR | Q92847 | 3/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6102593 | 1.00 | HTR1D (0.71) | HTR1DHTR1BHTR1AGHSRPDK1 | |
| SCHEMBL6101088 | 0.90 | HTR1D (0.69) | HTR1DHTR1BHTR1AGHSRPDK1 | |
| SCHEMBL6101016 | 0.89 | HTR1D (0.56) | HTR1DHTR1BHTR1APDK1PDK2 | |
| SCHEMBL6101995 | 0.86 | HTR1D (0.84) | HTR1DHTR1BHTR1AGHSRHTR2A | |
| SCHEMBL6098290 | 0.86 | HTR1D (0.73) | HTR1DHTR1BHTR1AGHSRHTR2A | |
| SCHEMBL6603817 | 0.83 | HTR1D (1.00) | HTR1DHTR1BHTR1AGHSRHTR2A | |
| SCHEMBL6099761 | 0.83 | HTR1D (0.68) | HTR1DHTR1BHTR1AGHSRHTR2A | |
| SCHEMBL6603811 | 0.83 | HTR1D (1.00) | HTR1DHTR1BHTR1AGHSRHTR2A | |
| SCHEMBL6100482 | 0.81 | HTR1D (0.78) | HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL6603418 | 0.80 | HTR1D (1.00) | HTR1DHTR1BHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368337-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS 5-HT1B LIGANDS | SMITHKLINE BEECHAM PLC (GB) | 2005-06-15 | — | — | EP | disclosed |
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142925-A1 | Piperazine derivatives their preparation and uses in therapy | NR3C2, NR2C2, NR3C1 | HTR1D 294/4885HTR1B 204/4885HTR1A 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.